Results 61 to 70 of about 1,442,988 (353)
Nature Communications, 2020 Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl +12 more
doaj +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Current Opinion in Biotechnology, 2020 Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire +3 more sources
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Life, 2021 Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen +2 more
doaj +1 more source
European Journal of Immunology, Volume 53, Issue 1, January 2023., 2023 B lineage cells have been identified as therapeutic targets in autoimmune diseases. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with a focus on inflammatory rheumatic diseases.
Ana Merino‐Vico +3 more
wiley +1 more source
Frontiers in ImmunologyBackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu +27 more
doaj +1 more source
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
Science Translational Medicine, 2021 Bispecific antibodies directed against T cell receptor β chains promote killing of human T cell cancers while preserving most healthy T cells. Specific bispecific antibodies A major challenge in efforts to develop immunotherapies for T cell cancers is ...
S. Paul +19 more
semanticscholar +1 more source
xTrimoABFold: De novo Antibody Structure Prediction without MSA [PDF]
arXiv, 2022 In the field of antibody engineering, an essential task is to design a novel antibody whose paratopes bind to a specific antigen with correct epitopes. Understanding antibody structure and its paratope can facilitate a mechanistic understanding of its function.
arxiv
Chemical generation of bispecific antibodies [PDF]
Proceedings of the National Academy of Sciences, 2010 Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang +21 more
openaire +3 more sources
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source
On Pre-trained Language Models for Antibody [PDF]
arXiv, 2023 Antibodies are vital proteins offering robust protection for the human body from pathogens. The development of general protein and antibody-specific pre-trained language models both facilitate antibody prediction tasks. However, there have been limited studies that comprehensively explore the representation capability of distinct pre-trained language ...
arxiv